Oseltamivir-Resistant Pandemic (HIN1) 2009 Treated with Nebulized Zanamivir
Tags: H1N1 (2009) influenza; DRUG resistance; PANDEMICS; INFLUENZA -- Treatment; CHILDREN -- Diseases; DRUGS -- Effectiveness
Related Articles
- Community-acquired Oseltamivir-Resistant Pandemic (H1N1) 2009 in Child, Israel. Zonis, Zeev; Engelhard, Dan; Hindiyeh, Musa; Ram, Daniela; Mandelboim, Michal; Mendelson, Ella; Glikman, Daniel // Emerging Infectious Diseases;Jun2010, Vol. 16 Issue 6, p1045
The article describes the case of a community-acquired oseltamivir-resistant pandemic influenza virus A (H1N1) infection in a two-year old boy in Israel reported in 2009. Real-time reverse transcription-polymerase chain reaction (RT-PCR) confirmed the child to have pandemic H1N1 infection....
- Pandemic (H1N1) 2009: a clinical spectrum in the general paediatric population. Larcombe, Penelope Jane; Moloney, Susan Evelyn; Schmidt, Peter Alan // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2011, Vol. 96 Issue 1, p96
This retrospective case series describes the clinical spectrum of 43 children with pandemic (H1N1) 2009 admitted to a single hospital in Australia during the peak winter flu season. Clinical features, diagnoses, length of hospitalisation and complications were reviewed in children up to 17 years...
- H1N1 influenza: Commentary on a pediatric outbreak. Wallace, Jennifer L.; Adams, Elizabeth E. // Infectious Diseases in Children;Aug2009, Vol. 22 Issue 8, p30
The author reflects on the pediatric outbreak of A H1N1 influenza in a boarding school in the U.S. in June 2009.
- In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir. Karthick, V.; Shanthi, V.; Rajasekaran, R.; Ramanathan, K. // Protoplasma;Feb2013, Vol. 250 Issue 1, p197
The recent H1N1 influenza pandemic has attracted worldwide attention due to the high infection rate. Oseltamivir is a new class of anti-viral agent approved for the treatment and prevention of influenza infections. The principal target for this drug is a virus surface glycoprotein, neuraminidase...
- Effects of Early Oseltamivir Therapy on Viral Shedding in 2009 Pandemic Influenza A (H1N1) Virus Infection. Ling, Li M.; Chow, Angela L.; Lye, David C.; Tan, Adriana S.; Krishnan, Prabha; Lin Cui; Win, Nwe N.; Chan, Monica; Lim, Poh L.; Lee, Cheng C.; Leo, Yee S. // Clinical Infectious Diseases;4/1/2010, Vol. 50 Issue 7, p963
Background. Pandemic influenza (H1N1) 2009 is susceptible to oseltamivir. There are few reports on its clinical and virologic response to oseltamivir. Methods. During the pandemic containment response in Singapore, all patients with positive polymerase chain reaction (PCR) results for pandemic...
- Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition. Vavricka, Christopher J.; Qing Li; Wu, Yan; Qi, Jianxun; Wang, Mingyang; Liu, Yue; Gao, Feng; Liu, Jun; Feng, Enguang; He, Jianhua; Wang, Jinfang; Liu, Hong; Jiang, Hualiang; Gao, George F. // PLoS Pathogens;Oct2011, Vol. 7 Issue 10, Special section p1
The 2009 H1N1 influenza pandemic (pH1N1) led to record sales of neuraminidase (NA) inhibitors, which has contributed significantly to the recent increase in oseltamivir-resistant viruses. Therefore, development and careful evaluation of novel NA inhibitors is of great interest. Recently, a...
- Early Pandemic Influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: A Clinical Virological and Epidemiological Analysis. Hien, Tran Tinh; Boni, Maciej F.; Bryant, Juliet E.; Tran Thuy Ngan; Wolbers, Marcel; Tran Dang Nguyen; Nguyen Thanh Truong; Nguyen Thi Dung; Do Quang Ha; Vo Minh Hien; Tran Tan Thanh; Le Nguyen Truc Nhu; Le Thi Tam Uyen; Pham Thi Nhien; Nguyen Tran Chinh; Nguyen Van Vinh Chau; Farrar, Jeremy; van Doorn, H. Rogier // PLoS Medicine;May2010, Vol. 7 Issue 5, p1
Background: To date, little is known about the initial spread and response to the 2009 pandemic of novel influenza A ("2009 H1N1") in tropical countries. Here, we analyse the early progression of the epidemic from 26 May 2009 until the establishment of community transmission in the second half...
- Rapid Selection of Oseltamivirand Peramivir-Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised Hosts. Memoli, Matthew J.; Hrabal, Rachel J.; Hassantoufighi, Arash; Eichelberger, Maryna C.; Taubenberger, Jeffery K. // Clinical Infectious Diseases;5/1/2010, Vol. 50 Issue 9, p1252
Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case...
- The dynamics of risk perceptions and precautionary behavior in response to 2009 (H1N1) pandemic influenza. Ibuka, Yoko; Chapman, Gretchen B.; Meyers, Lauren A.; Meng Li; Galvani, Alison P. // BMC Infectious Diseases;2010, Vol. 10 Issue 1, p296
Background: The trajectory of an infectious disease outbreak is affected by the behavior of individuals, and the behavior is often related to individuals' risk perception. We assessed temporal changes and geographical differences in risk perceptions and precautionary behaviors in response to...
